Manufacturer record
Nhika Pharmaceuticals: regulatory record
Last checked 3 November 2026. Source: CDSCO monthly NSQ alerts and state drug-testing laboratories
1 batch manufactured by Nhika Pharmaceuticals (Maharashtra) was declared Not of Standard Quality in September 2026. Records are batch-specific findings by government laboratories as published in CDSCO's monthly alerts; where a company has stated that a flagged batch was counterfeit, that statement is noted when reported.
Most recent flagged batch: MI012501, Albendazole Tablets 400 mg (exp Jun 2028). FDAL, M. S Chhatrapatri Sambhajinagar, F.D.A Mahrasthra State (state lab) found it not of standard quality: The Sample does not Comply with IP Requirements for the Dissolution Test. The sample is declared as Misbranded. Listed in the September 2026 alert.
Records by type
1 record linked to Nhika Pharmaceuticals in the datasets we hold. A zero means nothing is on record in those datasets, not that nothing ever happened. What the labels mean.
CDSCO drug alerts: Not of Standard Quality and spurious drugs
Scope. A company appearing here is not a finding that its products are unsafe. Regulatory actions can apply to one batch, one formulation, one period or one state. Always check the linked government document for the current position, and tell us if something is out of date. How we label records.
Flagged batches per year
All flagged batches
| Product | Batch | Reason declared NSQ | Tested by | Alert |
|---|---|---|---|---|
| Albendazole Tablets 400 mg | Batch MI012501Mfg Jul 2025 · Exp Jun 2028 | The Sample does not Comply with IP Requirements for the Dissolution Test. The sample is declared as MisbrandedDissolution | FDAL, M. S Chhatrapatri Sambhajinagar, F.D.A Mahrasthra StateState lab | Sep 2026 |
Right of reply. Manufacturers may submit a response or a laboratory re-test result; it is published unedited alongside this record. Submit a response.